GKB Ophthalmics Ltd (GKB) — shareholding pattern, promoter holding, financials and share price
About GKB Ophthalmics Ltd (GKB)
GKB Ophthalmics Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as GKB and on the BSE under scrip code 533212. Its ISIN is INE265D01015.
Incorporated in 1981, GKB Ophthalmics Ltd is engaged in the manufacture and sale of ophthalmic lenses made up of Glass and Plastic. [1]
GKB Ophthalmics specializes in manufacturing and exporting unfinished ophthalmic lenses from Goa, India.
The company has robust production capabilities with an installed capacity of 3 million lenses per annum.
Listed peers in Medical Equipment & Supplies: Shree Pacetronix Ltd, KMS Medisurgi Ltd, Amkay Products Ltd, Centenial Surgical Suture Ltd, Galaxy Medicare Ltd, Transpact Enterprises Ltd.
Valuation & Returns
10 Jul 2026At ₹59.99 a share on 10 Jul 2026, GKB Ophthalmics Ltd (GKB) was valued at a price-to-earnings ratio of 9.98x against an industry P/E of 44.11x and a price-to-book of 0.58x on a book value of ₹103.24 per share as of Mar 2025. Solomo computes return on equity of 5.82% and return on capital employed of 8.7% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 9.98x
- Industry P/E
- 44.11x
- P/B
- 0.58x
- EPS (TTM)
- ₹6.01
- Book value / share
- ₹103.24
- ROE
- 5.82%
- ROCE
- 8.7%
- ROA
- 2.42%
- Debt / equity
- 0.28x
- Dividend yield
- 0%
- EBITDA margin
- 6.04%
- 52-week range
- ₹45.25 – ₹91.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, GKB Ophthalmics Ltd (GKB) reported revenue of ₹149 crore, net profit of ₹3 crore and earnings per share of ₹2.42. That compares with revenue of ₹109 crore and net profit of ₹-7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹29.79 crore and net profit ₹1.12 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 71 | 75 | 88 | 109 | 149 |
| Net profit (₹ cr) | 2 | 0 | -3 | -7 | 3 |
| EPS (₹) | 2.52 | -0.34 | -5.57 | -13.97 | 2.42 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.09% | 5.08% | 6.58% | 23.50% |
| Profit growth | - | - | - | -137.58% |
| Stock price CAGR | -1% | -9% | -14% | -20% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.15% of GKB Ophthalmics Ltd (GKB) (up 0.02 pp QoQ), foreign institutional investors (FII) hold 1.79%. Market capitalisation was ₹30 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: KRISHNA MURARI GUPTA 5.54%, TANVI JIGNESH MEHTA 4.82%, SOMO VISION CO. LTD. 3.97%, BRIJENDRA KUMAR GUPTA 3.31%, HUF 1.8%, COEUS GLOBAL OPPORTUNITIES FUND 1.79%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.15% | - | 1.79% | - | 48.85% |
| Mar 2026 | 51.13% | - | 1.79% | - | 48.87% |
| Dec 2025 | 51.13% | - | 1.79% | - | 48.87% |
| Sep 2025 | 51.06% | - | 1.79% | - | 48.94% |
| Jun 2025 | 51.06% | - | 1.79% | - | 48.94% |
| Mar 2025 | 50.99% | - | 1.79% | - | 49.01% |
| Dec 2024 | 50.98% | - | 1.79% | - | 49.02% |
| Sep 2024 | 50.95% | - | 1.79% | - | 49.05% |